Literature DB >> 26112674

A biological tissue adhesive and dissolvent system for intraocular tumor plaque radiotherapy: an in vivo animal model experiment.

Ofira Zloto1, Dror Alezra2, Oded Sagiv1, Michael Belkin1, Vicktoria Vishnevskia Dai1, Iris Moroz1, Gahl Greenberg3, Elad Ben-Artsi1, Ido Didi Fabian4,5.   

Abstract

PURPOSE: To examine a novel biological adhesive and dissolvent system for plaque placement and removal using fibrin glue and urokinase, respectively, in an in vivo animal model.
METHODS: The study was performed on 23 rabbit eyes. Of these, eight underwent a technical feasibility study and ultrasonographic plaque displacement measurements, nine were examined clinically and by magnetic resonance imaging and histopathology for tissue reaction to the biological substances used, and in six the impact of fibrin glue as an orbital space occupier on intraocular pressure was assessed. In an additional ex vivo experiment, the glue's radiation attenuating properties were tested using an oncology EDR2 film.
RESULTS: Plaque horizontal movement throughout follow-up (7-10 days) was negligible (0.5 ± 0.2 mm), and there was no tilting whatsoever. In the tissue response experiment, no adverse effects were recorded after application of fibrin or urokinase throughout the 21-day follow-up period. Interestingly, a circumscribed local inflammatory response was noted in tissue surrounding the fibrin glue, and persisted at 21 days. In the orbital space-occupying experiment, application of 1 cc fibrin glue did not cause a significant elevation in intraocular pressure (IOP) (P = 0.06), and in the ex vivo experiment, there was no significant difference between radiation readings with and without glue separation of the radioactive sources and film (P = 0.065).
CONCLUSIONS: The adhesive and dissolvent system was feasible and safe for plaque placement and removal. It may be superior to conventional surgical plaque placement methods in eliminating the relatively common risk of plaque tilting and complications due to scleral suturing.

Entities:  

Keywords:  Fibrin glue; Plaque radiotherapy; Urokinase; Uveal melanoma

Mesh:

Substances:

Year:  2015        PMID: 26112674     DOI: 10.1007/s00417-015-3082-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  11 in total

1.  The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19.

Authors:  Lee M Jampol; Claudia S Moy; Timothy G Murray; Sandra M Reynolds; Daniel M Albert; Andrew P Schachat; Kenneth R Diddie; Robert E Engstrom; Paul T Finger; Kenneth R Hovland; Leonard Joffe; Karl R Olsen; Craig G Wells
Journal:  Ophthalmology       Date:  2002-12       Impact factor: 12.079

2.  [Urokinase treatment of threatened and acute myocardial infarct].

Authors:  P Babeau; P Pras
Journal:  Ann Med Interne (Paris)       Date:  1977-02

3.  Urokinase in the management of acute arterial and venous thrombosis.

Authors:  D Silver
Journal:  Arch Surg       Date:  1968-12

Review 4.  Plaque radiotherapy for the management of uveal metastasis.

Authors:  C L Shields
Journal:  Curr Opin Ophthalmol       Date:  1998-06       Impact factor: 3.761

5.  Three-dimensional ultrasonography of choroidal melanoma: localization of radioactive eye plaques.

Authors:  P T Finger; J M Romero; R B Rosen; R Iezzi; R Emery; A Berson
Journal:  Arch Ophthalmol       Date:  1998-03

6.  Intraoperative echographic localization of iodine 125 episcleral radioactive plaques for posterior uveal melanoma.

Authors:  J W Harbour; T G Murray; S F Byrne; J R Hughes; E K Gendron; F J Ehlies; A M Markoe
Journal:  Retina       Date:  1996       Impact factor: 4.256

7.  The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28.

Authors: 
Journal:  Arch Ophthalmol       Date:  2006-12

8.  Outcomes of iodine-125 plaque brachytherapy for uveal melanoma with intraoperative ultrasonography and supplemental transpupillary thermotherapy.

Authors:  Shahed N Badiyan; Rajesh C Rao; Anthony J Apicelli; Sahaja Acharya; Vivek Verma; Adam A Garsa; Todd DeWees; Christina K Speirs; Jose Garcia-Ramirez; Jacqueline Esthappan; Perry W Grigsby; J William Harbour
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-01-22       Impact factor: 7.038

9.  Regression of posterior uveal melanomas following cobalt-60 plaque radiotherapy.

Authors:  A F Cruess; J J Augsburger; J A Shields; L W Brady; A M Markoe; J L Day
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

10.  Tilting of radioactive plaques after initial accurate placement for treatment of uveal melanoma.

Authors:  Arghavan Almony; Sean Breit; Hui Zhao; Jose Garcia-Ramirez; David B Mansur; J William Harbour
Journal:  Arch Ophthalmol       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.